Jean-Michel Flaman

Jean-Michel Flaman

Auto-generated profile, based on publicly available information

Jean-Michel Flaman

Normandie University, UNIROUEN, Inserm U1245 and Rouen University Hospital, Department of Genetics, F 76000, Normandy Centre for Genomic and Personalized Medicine, Rouen, France

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 July 2015 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
GBGaëlle Bougeard
Gaëlle Bougeard
MRMariette Renaux-Petel
Mariette Renaux-Petel
JFJean-Michel Flaman
Jean-Michel Flaman
CCCamille Charbonnier
Camille Charbonnier
PFPierre Fermey
Pierre Fermey
TFThierry Frebourg
Thierry Frebourg
Purpose: The aim of the study was to update the description of Li-Fraumeni syndrome (LFS), a remarkable cancer predisposition characterized by extensive clinical heterogeneity. Patients and Methods: From 1,730 French patients suggestive of LFS, we identified 415 mutation carriers in 214 families harboring 133 distinct TP53 alterations and updated their clinical presentation. Results: The 322 affected carriers developed 552 tumors, and 43% had developed multiple malignancies. The mean age of first tumor onset was 24.9 years, 41% having developed a tumor by age 18. In childhood, the LFS tumor spectrum was characterized by osteosarcomas, adrenocortical carcinomas (ACC), CNS tumors, and soft tissue sarcomas (STS) observed in 30%, 27%, 26%, and 23% of the patients, respectively. In adults, the tumor distribution was characterized by the predominance of breast carcinomas observed in 79% of the females, and STS observed in 27% of the patients. The TP53 mutation detection rate in children presenting with ACC or choroid plexus carcinomas, and in females with breast cancer before age 31 years, without additional features indicative of LFS, was 45%, 42% and 6%, respectively. The mean age of tumor onset was statistically different (P < .05) between carriers harboring dominant-negative missense mutations (21.3 years) and those with all types of loss of function mutations (28.5 years) or genomic rearrangements (35.8 years). Affected children, except those with ACC, harbored mostly dominant-negative missense mutations. Conclusion: The clinical gradient of the germline TP53 mutations, which should be validated by other studies, suggests that it might be appropriate to stratify the clinical management of LFS according to the class of the mutation.

25 April 1995 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
JFJ M Flaman
J M Flaman
TFT Frebourg
T Frebourg
VMV Moreau
V Moreau
FCF Charbonnier
F Charbonnier
CMC Martin
C Martin
JBJ Benhattar
J Benhattar
Mutations in the p53 gene are implicated in the pathogenesis of half of all human tumors. We have developed a simple functional assay for p53 mutation in which human p53 expressed in Saccharomyces cerevisiae activates transcription of the ADE2 gene. Consequently, yeast colonies containing wild-type p53 are white and colonies containing mutant p53 are red. Since this assay tests the critical biological function of p53, it can distinguish inactivating mutations from functionally silent mutations. By combining this approach with gap repair techniques in which unpurified p53 reverse transcription-PCR products are cloned by homologous recombination in vivo it is possible to screen large numbers of samples and multiple clones per sample for biologically important mutations. This means that mutations can be detected in tumor specimens contaminated with large amounts of normal tissue. In addition, the assay detects temperature-sensitive mutants, which give pink colonies. We show here that this form of p53 functional assay can be used rapidly to detect germline mutations in blood samples, somatic mutations in tumors, and mutations in cell lines.

1 December 1995 in Human Molecular Genetics
Verified
Journal Article
Closed access
PDF file
DCDominique Campion
Dominique Campion
JFJean-Michel Flaman
Jean-Michel Flaman
ABAlexis Brice
Alexis Brice
DHDidier Hannequin
Didier Hannequin
BDBruno Dubois
Bruno Dubois
TFThierry Frebourg
Thierry Frebourg
We analyzed 12 families with autosomal dominant early-onset Alzheimer's disease (EOAD) for mutations in the coding region of the presenilin I (PSNLI) gene corresponding to the AD3 locus on chromosome 14q24.3. A total of eight missense mutations at codons 82, 115, 139, 163, 231, 264, 392, and 410, including six novel mutations, were identified in eight families. Cosegregation of the mutations with EOAD was confirmed in three families, one including 36 affected individuals. This study underlines the great allelic heterogeneity and the large distribution of the mutations within the PSNLI coding region. Our results support the notion that PSNLI is the major gene involved in autosomal dominant EOAD.

16 January 1997 in Oncogene
Verified
Journal Article
Closed access
FWF Waridel
F Waridel
AEA Estreicher
A Estreicher
LBL Bron
L Bron
JFJ-M Flaman
J-M Flaman
CFC Fontolliet
C Fontolliet
RIR Iggo
R Iggo

1 January 1994 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
JFJean-Michel Flaman
Jean-Michel Flaman
TFThierry Frebourg
Thierry Frebourg
VMViviane Moreau
Viviane Moreau
FCFrancoise Charbonnier
Francoise Charbonnier
CMCosette Martin
Cosette Martin
RIRichard Iggo
Richard Iggo

19 October 2008 in Human Genetics
Verified
Journal Article
Closed access
PDF file
EBElodie Bohers
Elodie Bohers
NSNasrin Sarafan-Vasseur
Nasrin Sarafan-Vasseur
ADAurélie Drouet
Aurélie Drouet
MPMarianne Paresy
Marianne Paresy
JLJean-Baptiste Latouche
Jean-Baptiste Latouche
TFThierry Frebourg
Thierry Frebourg